Subscribe

Hikal Limited (HIKAL.NS)

INR240.98 +3.76 (+1.59%)
IN NSE Healthcare Medical - Pharmaceuticals
Address Great Eastern Chambers 400614
Navi Mumbai, MH, IN
CEO Sameer Hiremath
Website hikal.com
IPO 2002-07-01
ISIN INE475B01022

Explore sections of this company profile

Also trades on Bombay Stock Exchange · HIKAL.BO (INR) National Stock Exchange of India · HIKAL.NS (INR)
Description

Hikal Limited, together with its subsidiaries, manufactures and sells various chemical intermediates, specialty chemicals, and active pharma ingredients to pharmaceutical, biotechnology, life sciences, animal health, crop protection, and specialty chemicals indusries. It operates through two segments, Pharmaceuticals and Crop Protection. The company also manufactures pesticides and herbicides, which include diuron tech, temephos tech, thiacloprid tech, clothianidin tech, dichloroaniline, N-bromosuccinimide, prothioconazole technical, trifloxystrobin technical, and BIT. In addition, it offers solutions in contract research, custom synthesis, and custom manufacturing of intermediates and active ingredients. Further, the company provides anti-convulsant, anti-inflammatory, analgesic, Anti-parasitic, anti-lipemic, anti-histaminic, anti-depressant, anti-psychotic, anti-emetic, anti-diabetic, anti-thrombotic, Anti-viral, anti-hypertensive, and Haemorheologic; animal health products, such as anti-tick, anti-parasitic, analgesic, anabolic steroids, female sex hormone, insecticide, and NSAID; and specialty biocides and antimicrobial actives, as well as additives for leather, paint coatings, paper, water treatment, personal care, building materials, and textile industries. The company also exports its products. It operates in India, the United States, Canada, Europe, South East Asia, and internationally. The company was formerly known as Hikal Chemical Industries Ltd. and changed its name to Hikal Limited in April 2000. Hikal Limited was incorporated in 1988 and is headquartered in Navi Mumbai, India.

Market Cap & Enterprise Value
Merger & Acquisition History

No mergers or acquisitions recorded for this company.

Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary Loading…
Indicator 1D1W2W3W1M
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
Averages
Trend
Price
Levels
Draw
INR240.98 +3.76 (+1.59%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
358.0K
Beta
1.75
Float Shares
38.08M
Free Float %
30.9%
Price Performance
1D5D1M3M6M YTD1Y3Y5Y10YMax
-12.29% -6.27% +2.57% -1.31% -12.92% -14.42% -48.35% -36.41% -50.71% +100.11% +1,903.20%
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
vs.
Loading histogram data…

Revenue flow

Revenue by geography

Revenue by segment

From To

Revenue composition

From To

By product

By geography

Financial Statements

Income Statement

Balance Sheet

Cash Flow Statement

Key Metrics

Financial Ratios

Employees

Financial Growth (CAGR)

Market Data

Price Targets & DCF
Current price
240.98
DCF (Levered) 6.56 -97.3%

DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.

Ratings Trend (MoM) 100% Bullish
Rating 2026-05 Change
Strong Buy 0 0
Buy 1 0
Hold 0 0
Sell 0 0
Strong Sell 0 0
Quality scores
Altman Z-Score
2.31
Grey zone
Piotroski F-Score
6 / 9
Average
MOAT Score
4 / 10
Developing
Composite Rating
C+
Overall Score
2 / 5
Medium
DCF Score
3 / 5
Medium
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
2 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
4 / 5
High
Operational MOAT
✗ Below peers
  • ✗
    Revenue growth Medical - Pharmaceuticals: +7.8%
    -7.9% Q1'26: -6.0% (vs Q1'25)
  • ✗
    EPS growth Medical - Pharmaceuticals: +20.2%
    -153.8% Q1'26: -71.3% (vs Q1'25)
  • ✓
    FCF margin FCF growth · Medical - Pharmaceuticals: +43.3%
    +8.2% ★ Q1'26: +0.0% (vs Q1'25)
  • ✗
    EBIT margin Medical - Pharmaceuticals: +6.8%
    +3.3% Q1'26: +12.2% (vs Q1'25)
  • ✗
    ROIC Medical - Pharmaceuticals: +6.1%
    +3.8% Q1'26: +17.0% (vs Q1'25)
  • ✓
    Share dilution Medical - Pharmaceuticals: +0.0%
    -0.1% ★ Q1'26: -0.2% (vs Q1'25)
  • ✗
    Debt / EBITDA Net debt/EBITDA · Medical - Pharmaceuticals: 0.21×
    5.49× Q1'26: 1.23× (vs Q1'25)
Valuation Multiples From To
Price Forecast (3Y) From To
Model
Adjust
P/E
Theoretical Return — If Invested Today

* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.

DCF Interactive Model (UFCF)
Projection years:
Market assumptions
▶ WACC components (optional)
Ke (Cost of Equity) = Rf + β (2.03) × ERP
WACC = 89% × Ke + 12% × Kd (20.0%) × (1−t)

Modifying these values recalculates WACC automatically.

Business assumptions
—
Current price: 240.98
Enterprise Value: — Equity Value: — Terminal Value: — TV as % of EV: —

Base values reflect the latest available data for this company and market conditions.

Consensus Estimates
Metric Mar 2006
actual 		Mar 2007
actual 		Mar 2014
actual 		Mar 2015
actual 		Mar 2016
actual 		Mar 2017
actual 		Mar 2018
actual 		Mar 2019
actual 		Mar 2020
actual 		Mar 2021
actual 		Mar 2022
actual 		Mar 2023
actual 		Mar 2024
actual 		Mar 2025
actual 		Mar 2026
1 Rev. Ana.
1 EPS Ana. 		Mar 2027
1 Rev. Ana.
1 EPS Ana. 		Mar 2028
1 Rev. Ana.
1 EPS Ana.
Revenue
4.56B
est: 5.03B (-9.4%)
4.36B
est: 4.74B (-8.0%)
8.28B
est: 8.49B (-2.5%)
8.59B
est: 9.27B (-7.3%)
9.08B
est: 10.51B (-13.6%)
10.33B
est: 10.01B (+3.3%)
12.99B
est: 12.99B (0.0%)
15.88B
est: 15.67B (+1.4%)
15.05B
est: 15.86B (-5.1%)
17.07B
est: 16.45B (+3.8%)
19.26B
est: 19.23B (+0.1%)
20.05B
est: 20.77B (-3.5%)
17.69B
est: 18.08B (-2.2%)
18.60B
est: 18.80B (-1.0%)
17.44B
17.44B – 17.44B
-7.2% YoY
19.62B
19.62B – 19.62B
+12.5% YoY
22.14B
22.14B – 22.14B
+12.9% YoY
EBITDA
586.01M
est: 831.91M (-29.6%)
519.11M
est: 767.18M (-32.3%)
2.11B
est: 1.37B (+53.4%)
1.74B
est: 1.53B (+13.9%)
1.66B
est: 1.74B (-4.4%)
1.98B
est: 1.65B (+19.6%)
2.43B
est: 2.15B (+13.1%)
2.89B
est: 1.80B (+60.9%)
2.55B
est: 1.90B (+34.3%)
3.24B
est: 1.59B (+103.9%)
3.40B
est: 1.81B (+88.4%)
2.60B
est: 1.92B (+35.4%)
2.67B
est: 2.99B (-10.6%)
3.33B
est: 2.52B (+32.4%)
2.34B
2.34B – 2.34B
-7.2% YoY
2.63B
2.63B – 2.63B
+12.5% YoY
2.97B
2.97B – 2.97B
+12.9% YoY
EBIT
409.94M
est: 537.15M (-23.7%)
328.83M
est: 495.35M (-33.6%)
1.53B
est: 887.62M (+72.0%)
1.10B
est: 988.96M (+11.5%)
986.85M
est: 1.12B (-12.0%)
1.28B
est: 1.07B (+20.1%)
1.57B
est: 1.39B (+13.4%)
1.97B
est: 1.90B (+3.3%)
1.73B
est: 2.14B (-19.3%)
2.38B
est: 1.78B (+34.1%)
2.45B
est: 2.02B (+20.9%)
1.51B
est: 2.15B (-29.8%)
1.49B
est: 1.93B (-22.9%)
1.99B
est: 1.60B (+24.0%)
1.49B
1.49B – 1.49B
-7.2% YoY
1.68B
1.68B – 1.68B
+12.5% YoY
1.89B
1.89B – 1.89B
+12.9% YoY
Net Income
335.21M
est: 421.88M (-20.5%)
191.07M
est: 348.95M (-45.2%)
638.99M
est: 892.57M (-28.4%)
404.05M
est: 798.12M (-49.4%)
412.01M
est: 1.01B (-59.0%)
677.16M
est: 611.92M (+10.7%)
772.27M
est: 804.37M (-4.0%)
1.03B
est: 920.01M (+12.0%)
844.35M
est: 1.06B (-20.1%)
1.33B
est: 855.64M (+55.6%)
1.60B
est: 974.29M (+64.7%)
783.82M
est: 1.03B (-24.3%)
696.02M
est: 678.54M (+2.6%)
908.00M
est: 714.75M (+27.0%)
197.17M
197.17M – 197.17M
-72.4% YoY
998.18M
998.18M – 998.18M
+406.3% YoY
1.37B
1.37B – 1.37B
+37.0% YoY
SGA
—
est: 301.74M (-100.0%)
520.31M
est: 278.26M (+87.0%)
261.41M
est: 498.62M (-47.6%)
297.27M
est: 555.54M (-46.5%)
280.03M
est: 629.98M (-55.5%)
304.37M
est: 599.75M (-49.3%)
325.41M
est: 778.44M (-58.2%)
364.90M
est: 2.52B (-85.5%)
395.86M
est: 2.64B (-85.0%)
526.57M
est: 2.89B (-81.8%)
813.05M
est: 3.29B (-75.3%)
864.85M
est: 3.50B (-75.3%)
895.18M
est: 1.08B (-17.4%)
2.47B
est: 2.02B (+22.3%)
1.87B
1.87B – 1.87B
-7.2% YoY
2.11B
2.11B – 2.11B
+12.5% YoY
2.38B
2.38B – 2.38B
+12.9% YoY
EPS
2.85
est: 3.42 (-16.7%)
1.67
est: 2.87 (-41.8%)
5.18
est: 7.34 (-29.4%)
3.28
est: 6.47 (-49.3%)
3.34
est: 8.15 (-59.0%)
5.46
est: 4.96 (+10.1%)
6.26
est: 6.52 (-4.0%)
8.36
est: 8.12 (+3.0%)
6.85
est: 8.40 (-18.5%)
10.80
est: 7.60 (+42.1%)
13.02
est: 14.80 (-12.0%)
6.36
est: 7.45 (-14.6%)
5.64
est: 5.50 (+2.5%)
7.36
est: 5.80 (+26.9%)
1.60
1.60 – 1.60
-72.4% YoY
8.10
8.10 – 8.10
+406.3% YoY
11.10
11.10 – 11.10
+37.0% YoY
Historical Ratings (3M)
Date Rating Overall DCF ROE ROA D/E P/E P/B
2026-05-29 C+ 2/5 3/5 1/5 1/5 2/5 1/5 4/5
2026-05-27 C- 1/5 1/5 1/5 1/5 2/5 1/5 3/5
2026-05-26 C- 1/5 1/5 1/5 1/5 2/5 1/5 3/5
2026-05-25 C- 1/5 1/5 1/5 1/5 2/5 1/5 3/5
2026-05-22 C- 1/5 1/5 1/5 1/5 1/5 1/5 3/5
2026-05-21 C- 1/5 1/5 1/5 1/5 1/5 1/5 3/5
2026-05-20 C- 1/5 1/5 1/5 1/5 1/5 1/5 3/5
2026-05-19 C- 1/5 1/5 1/5 1/5 1/5 1/5 3/5
2026-05-18 C- 1/5 1/5 1/5 1/5 1/5 1/5 3/5
2026-05-15 C- 1/5 1/5 1/5 1/5 1/5 1/5 3/5
2026-05-14 C- 1/5 1/5 1/5 1/5 1/5 1/5 3/5
2026-05-13 C- 1/5 1/5 1/5 1/5 1/5 1/5 3/5
2026-05-12 C- 1/5 1/5 1/5 1/5 1/5 1/5 3/5
2026-05-11 C- 1/5 1/5 1/5 1/5 1/5 1/5 3/5
2026-05-08 C- 1/5 1/5 1/5 1/5 1/5 1/5 3/5
2026-05-07 C- 1/5 1/5 1/5 1/5 1/5 1/5 3/5
2026-05-06 C- 1/5 1/5 1/5 1/5 1/5 1/5 3/5
2026-05-05 C- 1/5 1/5 1/5 1/5 1/5 1/5 3/5
2026-05-04 C- 1/5 1/5 1/5 1/5 1/5 1/5 3/5
2026-04-30 C- 1/5 1/5 1/5 1/5 1/5 1/5 3/5
2026-04-29 C- 1/5 1/5 1/5 1/5 1/5 1/5 3/5
2026-04-28 C- 1/5 1/5 1/5 1/5 1/5 1/5 3/5
2026-04-27 C- 1/5 1/5 1/5 1/5 1/5 1/5 3/5
2026-04-24 C- 1/5 1/5 1/5 1/5 1/5 1/5 3/5
2026-04-23 C- 1/5 1/5 1/5 1/5 1/5 1/5 3/5
2026-04-22 C- 1/5 1/5 1/5 1/5 1/5 1/5 3/5
2026-04-21 C- 1/5 1/5 1/5 1/5 1/5 1/5 3/5
2026-04-20 C- 1/5 1/5 1/5 1/5 1/5 1/5 3/5
2026-04-17 C- 1/5 1/5 1/5 1/5 1/5 1/5 3/5
2026-04-16 C- 1/5 1/5 1/5 1/5 1/5 1/5 3/5

Owner Earnings

Owner's Earnings (history) From To
Owner alignment
Owner's Earnings TTM
238.50M
OE per share TTM
1.92
Owner's Yield
0.99%
Maintenance CapEx ratio
219.39%
Maint CapEx / Avg PPE
70.6%

Ownership Overview

Ownership breakdown

Ownership breakdown not available.

At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)

No beneficial ownership filings recorded.

Institutional Activity (13F)

Institutional ownership trend

Institutional history not available.

Top institutional holders

Top holders not available.

ETF Ownership

Top ETFs holding this stock

This company is not held by any ETF in our universe.

Insider Activity

Insider Activity — Latest Quarter

No insider activity available.

Insider buys vs sells (history)

Insider history not available.

Recent insider transactions

No recent insider transactions.

Executive team

Top executives
EBIT / Employee
157.4K
Shares Outstanding
123.30M

Executive compensation

Executive compensation (annual)

Executive compensation not available.

CEO compensation breakdown

No CEO compensation history available.

Proxy statements

Proxy statements (DEF 14A)

No proxy statements available for this company yet.

Recent SEC filings

Recent SEC filings

No SEC filings available for this company yet.

Executive team

NameTitleCompensationGender
Jai Vishwanath Hiremath Founder & Executive Chairman 66M male
Sameer Hiremath MD & Vice Chairman 60M male
Manoj Mehrotra President of Pharmaceuticals Business — male
Mansukh Gokalbhai Patel Head of Sustainability & Corporate EHS — —
Rajasekhar Reddy Company Secretary & Compliance Officer — male
Ratish Jha President of Human Resources — male
Sarangan Suresh Whole Time Director — male
T. Devanathan Head of IP & Quality, Pharmaceuticals — —
Anish Dilip Swadi Senior President of Animal Health & Business Transformation — male
Vimal Deep Kulshrestha President of Crop Protection — male
Kuldeep Jain Chief Financial Officer — male
ESG Score History

No data available for this company.

Senate Trading Activity

No Senate trading activity found for this company.

House Trading Activity

No House trading activity found for this company.

Market share among peers
Peer comparison — filtered group (TTM)
Your opinion

Share your view on this stock and instantly see how the community has voted over the last 6 months.

These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.

Dividend yield history

Dividend history

Earnings history

Earnings reports

Stock splits

Related companies

Largest companies in Medical - Pharmaceuticals